Welcome to AlisLab

At AlisLab we are focused on understanding the molecular basis of allergenicity. Under the leadership of Dr. Araceli ("Ali") Diaz Perales, the group takes different approaches combining in vivo, in vitro, and in silico studies to target the key molecular factors that give place to sensitization to allergens of plant origin.

Our group is part of the International excellence Severo Ochoa CBGP Center. Come and meet us!

Alt a 1 - protein structure

Our research lines

Our main research activity focuses on the molecular events occurring in the sensitization to two model allergens: Pru p 3, the major food allergen from peach fruit, and Alt a 1, the principal aeroallergen from the fungus Alternaria alternata. By means of in vitro studies, models of in vivo cell systems, and in silico analyses that involve a variety of computational resources, we are deepening our understanding of the complex set of molecular processes that ultimately lead to allergy.

We are also interested in other topics such as

  • Production of new allergy diagnostic methods through microarrays.
  • Design of new strategies for treatment of allergies through production of hypoallergenic forms.

We are developing new computational methods to calculate properties, interactions, and structures of biomolecular systems involving protein and ligands with putative roles in immune processes relevant to allergy. Within this research line, we are particularly interested in incorporating electron density models to the computational study of protein-ligand and protein-protein complexes.

lab table

Meet our group!

We are a group of enthusiastic people with different academic backgrounds ranging from physical chemistry to biotechnology and cellular biology and who share a common passion for science.

Lab team pic on the snow

Discover our latest contributions

... in allergy, plant molecular biology, and structural biology.

Academy-Industry collaboration

We also work in a dynamic environment of collaboration among different agents (laboratories, hospitals, and companies) to accelerate innovation in treatments and diagnosis of allergy.